Literature DB >> 10383556

The prevalence and incidence of medical conditions in healthy pharmaceutical company employees who volunteer to participate in medical research.

S D Singh1, A J Williams.   

Abstract

AIMS: Although clinical research in healthy volunteers is commonly performed there have been few studies of the value of the medical screening of subjects. The aim of this study was to investigate the prevalence and incidence of medical conditions found during the medical screening of 'healthy' subjects employed in a pharmaceutical company who volunteered to participate in medical research.
METHODS: This was a retrospective study of the medical notes of all the subjects who volunteered for membership of the Zeneca Clinical Pharmacology Unit's healthy volunteer panel over a 4 year period from 1990 to 1994. The prevalence of medical conditions found at presentation was determined. The incidence of medical conditions during the 4 year observation period was also ascertained. Medical screening included a full medical history and examination, clinical chemistry, haematology and urinalysis screens, pulmonary function tests, ECGs, 24 h ambulatory cardiac monitoring and a request for information from the volunteer's General Practitioner.
RESULTS: Prevalence-1293 subjects volunteered to join the panel of which 156 subjects (12%) were not accepted at presentation including 141 (10. 9%) for medical reasons. The most medical common reasons were; previously diagnosed medical conditions (3.3%), cardiovascular abnormalities (1.9%), abnormal liver function tests (1.9%), anaemia (1.2%), hyperlipidaemia (1.1%), excess alcohol intake (0.6%) and thyroid disease (0.5%). Incidence-36 of the 1137 volunteers (0.8% per year) accepted onto the panel subsequently developed medical conditions of which the most common were; anaemia (0.29% per year), cardiovascular abnormalities (0.13% per year) and vasovagal syncope (0.13% per year).
CONCLUSIONS: This study demonstrates the importance of medical screening before healthy volunteers participate in clinical research.

Entities:  

Mesh:

Year:  1999        PMID: 10383556      PMCID: PMC2014880          DOI: 10.1046/j.1365-2125.1999.00961.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  The importance of general practitioner information in selection of volunteers for clinical trials.

Authors:  N Watson; P J Wyld
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

2.  Cardiac arrest following routine venipuncture.

Authors:  R Tizes
Journal:  JAMA       Date:  1976-10-18       Impact factor: 56.272

Review 3.  Hypothyroidism: screening and subclinical disease.

Authors:  A P Weetman
Journal:  BMJ       Date:  1997-04-19

4.  Healthy volunteer studies in Great Britain: the results of a survey into 12 months activity in this field.

Authors:  M Orme; J Harry; P Routledge; S Hobson
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

5.  Sudden death of a volunteer.

Authors:  A Darragh; M Kenny; R Lambe; I Brick
Journal:  Lancet       Date:  1985-01-12       Impact factor: 79.321

6.  The Hippocratian principle of 'primum nil nocere' demands that the metabolic state of a donor should be normalized prior to a subsequent donation of blood or plasma. How much blood, relative to his body weight, can a donor give over a certain period, without a continuous deviation of iron metabolism in the direction of iron deficiency?

Authors:  M E Conrad; W H Crosby; A Jacobs; J P Kaltwasser; J Nusbacher
Journal:  Vox Sang       Date:  1981 Nov-Dec       Impact factor: 2.144

7.  Vasovagal syncope.

Authors:  S Waddell
Journal:  Crit Care Nurse       Date:  1989-06       Impact factor: 1.708

8.  Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society.

Authors:  P Sever; G Beevers; C Bulpitt; A Lever; L Ramsay; J Reid; J Swales
Journal:  BMJ       Date:  1993-04-10

9.  A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953-1989.

Authors:  T M Munger; D L Packer; S C Hammill; B J Feldman; K R Bailey; D J Ballard; D R Holmes; B J Gersh
Journal:  Circulation       Date:  1993-03       Impact factor: 29.690

Review 10.  Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.

Authors:  R Collins; R Peto; S MacMahon; P Hebert; N H Fiebach; K A Eberlein; J Godwin; N Qizilbash; J O Taylor; C H Hennekens
Journal:  Lancet       Date:  1990-04-07       Impact factor: 79.321

View more
  4 in total

Review 1.  New approaches to the treatment and prevention of neurally mediated reflex (neurocardiogenic) syncope.

Authors:  Daniel P Melby; Joseph A Cytron; David G Benditt
Journal:  Curr Cardiol Rep       Date:  2004-09       Impact factor: 2.931

2.  Data driven evaluation of healthy volunteer characteristics at screening for phase I clinical trials to inform on study design and optimize screening processes.

Authors:  Annemie Deiteren; Erwin Coenen; Sabine Lenders; Peter Verwilst; Erik Mannaert; Freya Rasschaert
Journal:  Clin Transl Sci       Date:  2021-08-11       Impact factor: 4.689

3.  Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial.

Authors:  Susanne H Hodgson; Poppy Iveson; Jessica Larwood; Sophie Roche; Hazel Morrison; Catherine Cosgrove; Eva Galiza; Sabina Ikram; Nana-Marie Lemm; Savviz Mehdipour; Daniel Owens; Mihaela Pacurar; Michael Schumacher; Robert H Shaw; Saul N Faust; Paul T Heath; Andrew J Pollard; Katherine R W Emary; Katrina M Pollock; Rajeka Lazarus
Journal:  Clin Transl Sci       Date:  2021-10-20       Impact factor: 4.438

4.  Incidental diagnosis in healthy clinical trial subjects.

Authors:  Christopher J A Duncan; Rosalind Rowland; Patrick J Lillie; Joel Meyer; Susanne H Sheehy; Geraldine A O'Hara; Matthew Hamill; Hannah Donaldson; Laura Dinsmore; Ian D Poulton; Sarah C Gilbert; Helen McShane; Adrian V S Hill
Journal:  Clin Transl Sci       Date:  2012-03-06       Impact factor: 4.689

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.